First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases

First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4′-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2) Cushing’s Syndrome: Development of Highly Potent and Selective CYP11B1 Inhibitors of the (Pyridylmethyl)pyridine Type Synthesis and Evaluation of Imidazolylmethylenetetrahydronaphthalenes and Imidazolylmethyleneindanes:  Potent Inhibitors of Aldosterone Synthase Synthesis and Evaluation of (Pyridylmethylene)tetrahydronaphthalenes/-indanes and Structurally Modified Derivatives:  Potent and Selective Inhibitors of Aldosterone Synthase Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase Replacement of Imidazolyl by Pyridyl in Biphenylmethylenes Results in Selective CYP17 and Dual CYP17/CYP11B1 Inhibitors for the Treatment of Prostate Cancer